HLB has strengthened its control by acquiring additional shares of HLB Therapeutics.
On the 20th, HLB announced that it purchased 673,000 shares of HLB Therapeutics, increasing its stake from 5.51% to 6.25%.
HLB also purchased a total of 660,000 shares last November. Jin Yang-gon, chairman of HLB Group, and Ahn Ki-hong, CEO of HLB Therapeutics, also bought shares, demonstrating confidence in stabilizing HLB Therapeutics' management and its new drug development business.
HLB Therapeutics is currently conducting Phase 3 clinical trials for a neurotrophic keratitis (NK) treatment simultaneously in the United States and Europe. After completing the US clinical trial (SEER-2) and the European clinical trial (SEER-3) this year and confirming efficacy in key indicators, it plans to strengthen cooperation with global companies. It also plans to initiate the new drug approval application process.
HLB Therapeutics is working to enhance shareholder value through stock dividends. In December last year, it resolved to issue stock dividends amounting to 0.035 shares per common share, totaling 2.58 million shares. A regular shareholders' meeting will be held on the 26th to approve the dividend agenda.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
